Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Retained Earnings (2016 - 2025)

ProQR Therapeutics' Retained Earnings history spans 6 years, with the latest figure at $33.4 million for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 107.32% to $33.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.4 million, a 107.32% increase, with the full-year FY2025 number at $33.4 million, up 107.32% from a year prior.
  • Retained Earnings hit $33.4 million in Q4 2025 for ProQR Therapeutics, up from -$456.5 million in the prior quarter.
  • Over the last five years, Retained Earnings for PRQR hit a ceiling of $33.4 million in Q4 2025 and a floor of -$456.5 million in Q4 2024.
  • Historically, Retained Earnings has averaged -$237.4 million across 5 years, with a median of -$363.5 million in 2021.
  • Biggest five-year swings in Retained Earnings: soared 108.49% in 2022 and later plummeted 1496.81% in 2023.
  • Tracing PRQR's Retained Earnings over 5 years: stood at -$363.5 million in 2021, then skyrocketed by 108.49% to $30.9 million in 2022, then plummeted by 1496.81% to -$431.3 million in 2023, then fell by 5.84% to -$456.5 million in 2024, then soared by 107.32% to $33.4 million in 2025.
  • Business Quant data shows Retained Earnings for PRQR at $33.4 million in Q4 2025, -$456.5 million in Q4 2024, and -$431.3 million in Q4 2023.